Durable Responses After CD19-targeted CAR-T Cell Immunotherapy With Concurrent Ibrutinib for CLL After Prior Ibrutinib Failure
Hematological Oncology - United Kingdom
doi 10.1002/hon.126_2629
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley